Korro Bio, Inc. announces it has entered into a subscription agreement with a number of institutional accredited investors to issue 1,249,283 shares of common stock at a issue price of $56 per share for gross proceeds of $69,959,848 on April 17, 2024. The transaction will include participation from Deep Track Capital, as lead investor and Atlas Venture, Blue Owl Healthcare Opportunities, NEA, Rock Springs Capital, Tri Locum Partners, and other leading healthcare investors. The transaction is expected to close on April 22, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.5 USD | -0.26% | -5.01% | -11.33% |
May. 15 | HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating | MT |
May. 14 | Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.33% | 394M | |
+46.03% | 55.66B | |
-7.53% | 38.98B | |
+36.05% | 38.8B | |
-9.38% | 27.32B | |
+12.31% | 26.29B | |
-16.38% | 20.25B | |
+30.79% | 12.76B | |
+28.57% | 12.18B | |
-0.36% | 12.12B |
- Stock Market
- Equities
- KRRO Stock
- News Korro Bio, Inc.
- Korro Bio, Inc. announced that it expects to receive $69.959848 million in funding from Atlas Venture L.P.